Ohnishi S, Nakagawa M, Kobayashi N, Ogasawara M, Kiyama Y, Naohara T, Higa T, Kasai M
Department of Internal Medicine, Sapporo Hokuyu Hospital.
Rinsho Ketsueki. 1998 Sep;39(9):640-4.
Antithymocyte globulin (ATG) is an effective immunosuppressive therapy for aplastic anemia (AA). We administered ATG combined with cyclosporine (CyA), to 9 patients (4 men and 5 women; median age, 55 years). AA was severe in 8 patients and moderate in 1. The ATG and CyA regimen was the initial treatment for 3 patients, but sequential treatment for the other 6, who were refractory to other agents. Peripheral T lymphocytes, including CD4-positive and CD8-positive cells, decreased rapidly after treatment. Although 1 patient died of pulmonary hemorrhage during the 6-month period following treatment with this combined regimen, 3 showed a favorable response, 2 moderate response, and 3 no response at all. Adverse drug reactions, including transient fever and rash, were not severe. These findings suggested that ATG and CyA in combination are a safe and effective immunosuppressive regimen for initial and refractory patients with AA.
抗胸腺细胞球蛋白（ATG）是治疗再生障碍性贫血（AA）的一种有效免疫抑制疗法。我们对9例患者（4例男性，5例女性；中位年龄55岁）给予ATG联合环孢素（CyA）治疗。8例患者为重型AA，1例为中型AA。ATG和CyA方案是3例患者的初始治疗，但另外6例对其他药物难治的患者则为序贯治疗。包括CD4阳性和CD8阳性细胞在内的外周血T淋巴细胞在治疗后迅速减少。尽管1例患者在接受该联合方案治疗后的6个月内死于肺出血，但3例反应良好，2例中度反应，3例无反应。包括短暂发热和皮疹在内的药物不良反应并不严重。这些发现表明，ATG和CyA联合应用对于初治和难治性AA患者是一种安全有效的免疫抑制方案。
